LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma

Peter MacCallum Cancer Centre, Melbourne

East St Kilda Eye Clinic, Melbourne

Universitätsspital Zürich, Zurich Flughafen

Memorial Sloan Kettering Cancer Center Attn: Geny O'neill, New York

Memorial Sloan Kettering Cancer Center Inpatient Hospital & Main Campus, New York

Memorial Sloan Kettering Cancer Center- Outpatient Clinic, New York

Sarah Cannon Research Institute, Nashville

Tennessee Oncology, PLLC, Nashville

Uniklinik Köln, Cologne

University Clinic Heidelberg PPDS, Heidelberg

Azienda Ospedaliera Monaldi, Napoli

U.O.C. Oncologia Medica e Terapie Innovative Dipartimento di Melanoma IRCCS Fondazione G. Pascale, Napoli

Städtisches Klinikum München, München

University of California Los Angeles, Los Angeles

Cancer Care Center, Los Angeles

Doris Stein Research Center Building, Los Angeles

Ronald Reagan UCLA Medical Center Drug Information Center Department of Pharmaceutical Services, Los Angeles

UCLA Dermatology Clinic, Los Angeles

UCLA Oncology Center, Los Angeles

UCLA Radiology, Los Angeles

Universitätsklinikum Würzburg, Würzburg

Universitätsklinikum Würzburg, Würzburg

OHSU Knight Cancer Institute, Portland

OHSU Center for Health and Healing 2, Portland

OHSU Center for Health and Healing, Portland

OHSU Research Pharmacy Services, Portland

Oregon Health and Science University, Portland

Princess Margaret Cancer Center, Toronto

Sir Mortimer B. Davis-Jewish General Hospital, Monteral

Het Nederlands Kanker Instituut Antoni Van Leeuwenhoek Ziekenhuis, Amsterdam

Hospital Universitario Vall d'Hebrón - PPDS, Barcelona Cataluna

Churchill Hospital, Oxford